A Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg
Latest Information Update: 29 Jan 2022
Price :
$35 *
At a glance
- Drugs Gemtuzumab ozogamicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms MYLOR
- 14 Dec 2021 Results assessing the efficacy and the safety of GO-based regimen in R/R adult AML patients, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
- 23 Jan 2018 Status changed from not yet recruiting to recruiting.
- 21 Sep 2017 New trial record